Celgene Corporation to Announce Fourth Quarter and Full-Year 2008 Results on January 29, 2009.SUMMIT, N.J. -- Celgene Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CELG) senior management will host a conference call and live audio webcast on Thursday, January 29, 2009 at 9 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy to discuss the company's fourth quarter and full-year 2008 financial and operational results. The webcast will be available in the investor relations Investor relations The process by which the corporation communicates with its investors. section of the company's Web site at www.celgene.com. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com This release contains certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. which involve known and unknown risks, delays, uncertainties and other factors not under the company's control, which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory authorities, and those factors detailed in the company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion